Studies related to Diarrhea and Lactobacillus reuteri

A Randomized, Double-blind, Placebo-controlled Pilot Study Of Lactobacillus Reuteri ATCC 55730 For The Prevention Of Antibiotic-associated Diarrhea In Hospitalized Adults

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 23
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
In hospitalized patients who tested positive for _clostridium officinale_ (known to cause diarrhea) and were already on antibiotic therapy, supplementation of _l. reuteri_ ATCC 55730 at 10^8^ CFU daily for 2-4 weeks significantly reduced the frequency of antibiotic-induced diarrhea from 50% in placebo down to 7.7%.